FDA Opens CBD Regulatory Path Docket, Warns Firms On Claims Missteps
Executive Summary
With public hearing scheduled May 31 and a related public comment period, FDA "is interested in whether there are particular safety concerns that we should be aware of as we consider the FDA’s regulatory oversight and monitoring" of CBD products. Also influencing FDA's consideration is that CBD and other cannabis-derived substances are approved and being studied as drugs products, making their use as dietary ingredients noncompliant with agency regulations.
New to HBW Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
